Surveyed EU5 Medical Oncologists Prescribe Iressa or Tarceva as a First-Line
Treatment to an Average of 70 Percent of Their Confirmed EGFR-Mutation
Positive NSCLC Patients
Interviewed Payers Say Biomarker-Driven Prescribing is an NSCLC Market Access
Lever, But Optimal Pivotal Trial Design is Also Key, According to a New Report
from Decision Resources
BURLINGTON, Mass., Oct. 31, 2013
BURLINGTON, Mass., Oct. 31, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that surveyed medical oncologists across the EU5
(France, Germany, Italy, Spain, and the United Kingdom) currently prescribe
the reversible epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors Tarceva (Roche) or Iressa (AstraZeneca) as first-line treatment to
an average of 70 percent of their drug-treated non-small-cell lung cancer
(NSCLC) patients with non-squamous tumors confirmed to be harboring an
activating EGFR mutation. Coupled with first-line prescribing of Pfizer's
Xalkori to 36 percent of respondents' ALK translocation-positive NSCLC
patients, on average—despite health technology assessment (HTA) complexities
in some countries—this demonstrates the increasing importance of
biomarker-driven prescribing in NSCLC in the EU5.
The new European Physician and Payer Forum report entitled Non-Small-Cell Lung
Cancer: Drivers of European Prescribing and Reimbursement in an Indication
with High Unmet Need at a Time of Increasing Austerity also finds that while
interviewed payers confirm that a strongly predictive biomarker and highly
predefined target population are key tools for access to the highly
competitive NSCLC market, manufacturers seeking to penetrate this space must
optimize pivotal trial design and value dossier preparation. Head-to-head
studies incorporating strong biomarkers that show robust survival benefits
over suitable comparators are increasingly vital in all EU5 countries as
cost-constrained healthcare authorities strive to draw out value for money.
The findings also reveal that while all or almost all surveyed oncologists
currently test some tumors for EGFR mutation and ALK translocation, the rate
of testing is constrained by the need to treat before results are obtained and
the lack of tissue for testing and healthcare authority restrictions on
patient criteria. In addition, definitive results of ALK testing especially
are not always obtained.
"Companion diagnostic tests that use surrogate samples, such as serum, plasma,
bronchial alveolar lavage and fine needle aspirates, could improve uptake of
targeted agents," said Decision Resources Business Insights Analyst Sam
Mentzer. "Furthermore, well-designed, easily administered cost-sharing schemes
can be a key prescribing differentiator for NSCLC, especially in Italy and the
United Kingdom, and increasingly in Spain. As cost-sharing schemes become more
prevalent, funding of diagnostic testing could be an additional leveraging
tool, country-specific legalities permitting."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.